RESUMO
Nuclear fusion is one of the most attractive alternatives to carbon-dependent energy sources1. Harnessing energy from nuclear fusion in a large reactor scale, however, still presents many scientific challenges despite the many years of research and steady advances in magnetic confinement approaches. State-of-the-art magnetic fusion devices cannot yet achieve a sustainable fusion performance, which requires a high temperature above 100 million kelvin and sufficient control of instabilities to ensure steady-state operation on the order of tens of seconds2,3. Here we report experiments at the Korea Superconducting Tokamak Advanced Research4 device producing a plasma fusion regime that satisfies most of the above requirements: thanks to abundant fast ions stabilizing the core plasma turbulence, we generate plasmas at a temperature of 100 million kelvin lasting up to 20 seconds without plasma edge instabilities or impurity accumulation. A low plasma density combined with a moderate input power for operation is key to establishing this regime by preserving a high fraction of fast ions. This regime is rarely subject to disruption and can be sustained reliably even without a sophisticated control, and thus represents a promising path towards commercial fusion reactors.
RESUMO
OBJECTIVE: In this study, we aimed to assess the safety and efficacy of Janus kinase (JAK) inhibitors in patients with ankylosing spondylitis (AS). METHODS: We conducted a Bayesian network meta-analysis using direct and indirect data from randomized controlled trials (RCTs), and examined the safety and efficacy of JAK inhibitors in active AS patients exhibiting inadequate response or intolerance to two or more non-steroidal anti-inflammatory drugs (NSAIDs). RESULTS: RCTs included a total of 406 patients (203 experimental subjects and 203 controls) from three studies on upadacitinib, filgotinib, and tofacitinib. Assessment of SpondyloArthritis International Society 20% improvement (ASAS20), ASAS40, and ASAS5/6 responses were significantly higher in the JAK inhibitor group than in the placebo group. Other efficacy outcomes, such as ASAS partial remission, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50), Ankylosing Spondylitis Disease Activity Score (ASDAS), Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) scores, and Bath Ankylosing Spondylitis Functional Index (BASFI) were also significantly higher in the JAK inhibitor group compared to the placebo group. The JAK inhibitors significantly improved disease activity (ASAS partial remission, BASDAI50, ASDAS), function (BASFI), and MRI outcomes (SPARCC MRI spine). However, the incidence of adverse events (AEs) and serious adverse events (SAEs), and the rate of withdrawal attributed to AEs did not differ between the JAK inhibitor and placebo groups. CONCLUSION: JAK inhibitors were effective in active AS patients exhibiting an inadequate response or intolerance to two or more NSAIDs, without the risk of SAEs; this suggests that based on our data, studies are warranted to further investigate the use of JAK inhibitors for treating AS.
Assuntos
Inibidores de Janus Quinases , Espondilartrite , Espondilite Anquilosante , Humanos , Inibidores de Janus Quinases/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Coluna Vertebral , Espondilite Anquilosante/diagnóstico , Espondilite Anquilosante/tratamento farmacológico , Resultado do TratamentoRESUMO
OBJECTIVE: Evaluation of the effectiveness and safety of secukinumab and ixekizumab in active ankylosing spondylitis (AS) patients. METHODS: A Bayesian network meta-analysis was conducted using direct and indirect data from five randomized controlled trials that examined the efficacy and safety of secukinumab 150â¯mg every 4 weeks and ixekizumab 80â¯mg every 2 weeks (IXEQ2W) or every 4 weeks (IXEQ4W) in active AS patients. RESULTS: Data from 1433 patients were analyzed. The Assessment of Spondyloarthritis International Society evaluation 20% response rates (ASAS20) were significantly higher with secukinumab 150â¯mg, IXEQ2W, IXEQ2W, and adalimumab 40â¯mg (odds ratio [OR] 2.75, 95% Bayesian credible interval [CrI] 2.04-3.69; OR 2.59, 95% CrI 1.69-3.98; OR 2.45, 95% CrI 1.60-3.75; and OR 1.94, 95% CrI 1.13-3.37, respectively) compared to the placebo group. Efficacies of secukinumab and ixekizumab were numerically higher compared to adalimumab 40â¯mg, although there was no significant difference in the ASAS20 response rates. The ASAS40 response rate showed a pattern of distribution similar to the ASAS20 response rate, with the exception of the ixekizumab group, which was associated with the most favorable surface under the cumulative ranking curve (SUCRA) for the ASAS40 response rate. Based on the SUCRA rating, secukinumab 150â¯mg had the highest probability of being the best ASAS20 response rate therapy, followed by IXEQ2W, IXEQ4W, adalimumab 40â¯mg, and placebo. There was no significant difference between the treatments regarding the number of serious adverse events (SAEs). CONCLUSION: Secukinumab and ixekizumab were effective in active AS treatment, without the risk of SAEs.
Assuntos
Antirreumáticos , Espondilite Anquilosante , Anticorpos Monoclonais Humanizados , Antirreumáticos/efeitos adversos , Teorema de Bayes , Humanos , Espondilite Anquilosante/tratamento farmacológico , Resultado do TratamentoRESUMO
OBJECTIVE: The relative efficacy and tolerability of tofacitinib, baricitinib, upadacitinib, and filgotinib were assessed in patients with rheumatoid arthritis (RA) with inadequate responses to biologic disease-modifying antirheumatic drugs (bDMARDs). METHODS: We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in RA patients with inadequate responses to bDMARDs. RESULTS: Four RCTs comprising 1399 patients met the inclusion criteria. Tofacitinib, baricitinib, upadacitinib, and filgotinib achieved significant American College of Rheumatology 20% (ACR20) responses versus placebo. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that upadacitinib 15â¯mg had the highest probability of being the best treatment for achieving the ACR20 response rate, followed by filgotinib 200â¯mg, baricitinib 4â¯mg, filgotinib 100â¯mg, tofacitinib 5â¯mg, and placebo. The ranking in SUCRA based on the ACR50 response rate indicated that baricitinib 4â¯mg had the highest probability of achieving the ACR50 response rate, followed by filgotinib 200â¯mg, tofacitinib 5â¯mg, upadacitinib 15â¯mg, filgotinib 100â¯mg, and placebo. Tofacitinib 5â¯mg showed a significantly higher ACR70 response rate than filgotinib 100â¯mg and upadacitinib 15â¯mg. Tofacitinib 5â¯mg, filgotinib 200â¯mg, and placebo showed a significantly lower serious adverse event rate than upadacitinib 15â¯mg. CONCLUSION: Tofacitinib, baricitinib, upadacitinib, and filgotinib were effective treatment options for RA patients with an inadequate response to bDMARDs but with different efficacy and safety profiles.
Assuntos
Antirreumáticos , Artrite Reumatoide , Produtos Biológicos , Antirreumáticos/efeitos adversos , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/tratamento farmacológico , Azetidinas , Produtos Biológicos/uso terapêutico , Compostos Heterocíclicos com 3 Anéis , Humanos , Metotrexato/uso terapêutico , Piperidinas , Purinas , Pirazóis , Piridinas , Pirimidinas , Pirróis/efeitos adversos , Sulfonamidas , Resultado do Tratamento , TriazóisRESUMO
OBJECTIVE: To systematically investigate the relationship between circulating interleukin-23 (IL23) levels and ankylosing spondylitis (AS) and establish a correlation between these hematological indices and AS activity/severity. METHODS: We searched the Medline, Embase, and Cochrane databases; performed a meta-analysis comparing serum/plasma IL23 levels in patients with AS to those of controls; and examined the correlation coefficients between serum/plasma IL23 levels and AS activity. RESULTS: Ten studies including 1724 patients with AS and 1589 controls were included in this meta-analysis. This meta-analysis showed that circulating IL23 levels were significantly higher in the AS than in the control group (standardized mean difference [SMD] 1.479; 95% confidence interval [CI] 0.308-2.650; pâ¯= 0.013). Stratification by ethnicity showed a significantly increased IL23 level in the AS group in an Asian population (SMD 1.551; 95% CI 0.543-2.558; pâ¯= 0.003). Stratification by adjustment for age and sex revealed significantly higher IL23 levels in the AS adjustment group. Subgroup analysis of sample size showed a significantly higher IL23 level for a small (nâ¯< 150) sample number in the AS group. Meta-analysis of correlation coefficients revealed that the IL23 level was positively associated with the Bath Ankylosing Spondylitis Metrology Index (BASMI; correlation coefficient 0.464; 95% CI 0.027-0.752; pâ¯= 0.038), erythrocyte sedimentation rate (ESR; correlation coefficient 0.258; 95% CI 0.076-0.422; pâ¯= 0.006), and Creactive protein (CRP; correlation coefficient 0.291; 95% CI 0.053-0.498; pâ¯= 0.017). CONCLUSION: This meta-analysis demonstrated that the circulating IL23 level is significantly higher in patients with AS, and a significant positive correlation exists between the circulating IL23 level and BASMI, ESR, and CRP.
Assuntos
Espondilite Anquilosante , Sedimentação Sanguínea , Proteína C-Reativa/análise , Humanos , Interleucina-23 , Índice de Gravidade de Doença , Espondilite Anquilosante/diagnósticoRESUMO
OBJECTIVE: This study aimed to assess the efficacy and safety of mycophenolate mofetil (MMF) versus cyclophosphamide (CYC) in patients with active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). METHODS: We performed a meta-analysis of four randomized clinical trials (RCTs; 300 patients) to examine the relative efficacy and safety of MMF compared to CYC in patients with active AAV. RESULTS: There was no significant difference in remission at 6 months between MMF and CYC (odds ratio [OR] 1.311, 95% confidence interval [CI] 0.570-3.017, Pâ¯= 0.524). Additionally, the relapse rate did not differ between the MMF and CYC groups (OR 1.331, 95% CI 0.497-3.568, Pâ¯= 0.570). There was no significant difference in serious adverse event (SAE; OR 1.232, 95% CI 0.754-2.014, Pâ¯= 0.404) and infection rates (OR 0.958, 95% CI 0.561-1.634, Pâ¯= 0.873) between the MMF and CYC groups. Some heterogeneity was found in the meta-analysis of remission and relapse rates (I2â¯= 57.4%, 63.4%), but no between-study heterogeneity was found during the meta-analysis of SAE and infection rate. Egger's regression test showed no evidence of publication bias (Egger's regression test P-values >0.1). CONCLUSION: MMF was an equally effective alternative treatment to CYC and MMF was comparable to CYC in patients with active AAV in terms of safety, suggesting that MMF can be used as an alternative to CYC for remission induction in AAV.
Assuntos
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos , Nefrite Lúpica , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/tratamento farmacológico , Anticorpos Anticitoplasma de Neutrófilos , Ciclofosfamida/efeitos adversos , Humanos , Imunossupressores/efeitos adversos , Ácido Micofenólico/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Indução de Remissão , Resultado do TratamentoRESUMO
An assessment of the relative efficacy and tolerability of tofacitinib, baricitinib, upadacitinib, and filgotinib compared to those of methotrexate (MTX) was performed in disease-modifying antirheumatic drug (DMARD)-naive patients with rheumatoid arthritis (RA). We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) so as to examine the efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib, and MTX in DMARD-naïve RA patients. Four RCTs comprising 2185 patients met the inclusion criteria. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that upadacitinib 15â¯mg had the highest probability of achieving the American College of Rheumatology 20% (ACR20) response rate, followed by baricitinib 4â¯mg, tofacitinib 5â¯mg, filgotinib 200â¯mg, and MTX. Tofacitinib, baricitinib, upadacitinib, and filgotinib treatments achieved significantly higher ACR50 and ACR70 responses compared to MTX. Tofacitinib 5â¯mg had the highest probability of achieving the ACR50 and ACR70 response rates, followed by upadacitinib 15â¯mg, baricitinib 4â¯mg, filgotinib 200â¯mg, and MTX. The safety analysis based on serious adverse events, adverse events (AEs), and withdrawals due to AEs revealed no statistically significant differences between the respective intervention groups. In conclusion, tofacitinib, baricitinib, upadacitinib, and filgotinib were effective treatment options for DMARD-naïve RA patients, suggesting a difference in efficacy and safety among the different JAK inhibitors.
Assuntos
Antirreumáticos , Artrite Reumatoide , Antirreumáticos/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Azetidinas , Teorema de Bayes , Quimioterapia Combinada , Compostos Heterocíclicos com 3 Anéis , Humanos , Metotrexato/efeitos adversos , Piperidinas , Purinas , Pirazóis , Piridinas , Pirimidinas , Sulfonamidas , Resultado do Tratamento , TriazóisRESUMO
We surveyed randomized controlled trials (RCTs) examining the efficacy and safety of anifrolumab 300â¯mg in patients with active systemic lupus erythematosus (SLE) despite receiving standard therapy, using MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis performed to determine treatment efficacy and safety outcomes of three RCTs (459 patients and 468 controls) revealed that the BICLA responses were significantly higher in the anifrolumab group than in the placebo group (ORâ¯= 2.071, 95%CI 1.575-2.725, pâ¯< 0.001). Steroid reduction and CLASI reduction were also significantly higher in the anifrolumab group than in the placebo group (ORâ¯= 1.811, 95%CIâ¯= 1.308-2.506, pâ¯< 0.001; ORâ¯= 2.245, 95%CIâ¯= 1.437-3.506, pâ¯< 0.001). Compared with placebo, anifrolumab significantly increased the SRI7 and SRI8 responses in SLE patients (ORâ¯= 1.866, 95%CIâ¯= 1.372-2.536, pâ¯< 0.001; ORâ¯= 1.925, 95%CIâ¯= 1.387-2.672, pâ¯< 0.001). The SRI4, 5, and 6 responses also tended to be higher in the anifrolumab group than in the placebo group. Adverse event incidence was significantly higher in the anifrolumab group than in the placebo group (ORâ¯= 1.815, 95%CIâ¯= 1.262-2.611, pâ¯= 0.001); serious adverse events were significantly lower in the anifrolumab group than in the placebo group (ORâ¯= 0.679, 95%CIâ¯= 0.468-0.986, pâ¯= 0.042). Herpes zoster infection was significantly higher in the anifrolumab group than in the placebo group (ORâ¯= 4.089, 95%CIâ¯= 1.750-9.522, pâ¯= 0.001). Anifrolumab is effective for treating active SLE. However, anifrolumab increased the incidence of herpes zoster infection compared with placebo.
Assuntos
Anticorpos Monoclonais Humanizados , Lúpus Eritematoso Sistêmico , Humanos , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do TratamentoRESUMO
STUDY QUESTION: Does an early proliferative phase endometrial biopsy harvested during ovarian stimulation harbour information predictive of the outcome following fresh embryo transfer (ET) in that same cycle? SUMMARY ANSWER: Transcriptome analysis of the whole-tissue endometrium did not reveal significant differential gene expression (DGE) in relation to the outcome; however, the secretome profile of isolated, cultured and in vitro decidualized endometrial stromal cells (EnSCs) varied significantly between patients who had a live birth compared to those with an implantation failure following fresh ET in the same cycle as the biopsy. WHAT IS KNOWN ALREADY: In the majority of endometrial receptivity research protocols, biopsies are harvested during the window of implantation (WOI). This, however, precludes ET in that same cycle, which is preferable as the endometrium has been shown to adapt over time. Endometrial biopsies taken during ovarian stimulation have been reported not to harm the chances of implantation, and in such biopsies DGE has been observed between women who achieve pregnancy versus those who do not. The impact of the endometrial proliferative phase on human embryo implantation remains unclear, but deserves further attention, especially since in luteal phase endometrial biopsies, a transcriptional signature predictive for repeated implantation failure has been associated with reduced cell proliferation, possibly indicating proliferative phase involvement. Isolation, culture and in vitro decidualization (IVD) of EnSCs is a frequently applied basic research technique to assess endometrial functioning, and a disordered EnSC secretome has previously been linked with failed implantation. STUDY DESIGN, SIZE, DURATION: This study was nested in a randomized controlled trial (RCT) investigating the effect of endometrial scratching during the early follicular phase of ovarian stimulation on clinical pregnancy rates after IVF/ICSI. Of the 96 endometrial biopsies available, after eliminating those without fresh ET and after extensive matching in order to minimize the risk of potential confounding, 18 samples were retained to study two clinical groups: nine biopsies of patients with a live birth versus nine biopsies of patients with an implantation failure, both following fresh ET performed in the same cycle as the biopsy. We studied the proliferative endometrium by analysing its transcriptome and by isolating, culturing and decidualizing EnSCs in vitro. We applied this latter technique for the first time on proliferative endometrial biopsies obtained during ovarian stimulation for in-cycle outcome prediction, in an attempt to overcome inter-cycle variability. PARTICIPANTS/MATERIALS, SETTING, METHODS: RNA-sequencing was performed for 18 individual whole-tissue endometrial biopsies on an Illumina HiSeq1500 machine. DGE was analysed three times using different approaches (DESeq2, EdgeR and the Wilcoxon rank-sum test, all in R). EnSC isolation and IVD was performed (for 2 and 4 days) for a subset of nine samples, after which media from undifferentiated and decidualized cultures were harvested, stored at -80°C and later assayed for 45 cytokines using a multiplex suspension bead immunoassay. The analysis was performed by partial least squares regression modelling. MAIN RESULTS AND THE ROLE OF CHANCE: After correction for multiple hypothesis testing, DGE analysis revealed no significant differences between endometrial samples from patients who had a live birth and those with an implantation failure following fresh ET. However secretome analysis after EnSC isolation and culture, showed two distinct clusters that clearly corresponded to the two clinical groups. Upon IVD, the secretome profiles shifted from that of undifferentiated cells but the difference between the two clinical groups remained yet were muted, suggesting convergence of cytokine profiles after decidualization. LIMITATIONS, REASONS FOR CAUTION: Caution is warranted due to the limited sample size of the study and the in vitro nature of the EnSC experiment. Validation on a larger scale is necessary, however, hard to fulfil given the very limited availability of in-cycle proliferative endometrial biopsies outside a RCT setting. WIDER IMPLICATIONS OF THE FINDINGS: These data support the hypothesis that the endometrium should be assessed not only during the WOI and that certain endometrial dysfunctionalities can probably be detected early in a cycle by making use of the proliferative phase. This insight opens new horizons for the development of endometrial tests, whether diagnostic or predictive of IVF/ICSI treatment outcome. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by Fonds Wetenschappelijk Onderzoek (FWO, Flanders, Belgium, 11M9415N, 1 524 417N), Wetenschappelijk Fonds Willy Gepts (WFWG G160, Universitair Ziekenhuis Brussel, Belgium) and the National Medicine Research Council (NMRC/CG/M003/2017, Singapore). There are no conflicts of interests. TRIAL REGISTRATION NUMBER: NCT02061228.
Assuntos
Transferência Embrionária , Injeções de Esperma Intracitoplásmicas , Bélgica , Endométrio , Feminino , Humanos , Gravidez , SingapuraRESUMO
BACKGROUND AND PURPOSE: Anosognosia refers to a deficit of self-awareness or impaired insight for cognitive and behavioral problems. Cognitive anosognosia was explored in de novo patients with Parkinson's disease (PD) and its relationship to cognitive function and neuropsychiatric symptoms was investigated. METHODS: The cross-sectional study enrolled 340 drug-naïve patients with PD. According to the presence of mild cognitive impairment (MCI) and subjective cognitive complaint, patients were classified as patients with cognitive anosognosia (PD-CA, n = 74), with normal cognitive recognition (PD-NR, n = 184) or with cognitive underestimation (PD-CU, n = 82). After controlling for covariates, cognitive performance and neuropsychiatric symptoms were compared between the PD groups. RESULTS: Cognitive anosognosia was found in 21.8% of patients with de novo PD. The PD-CA group showed poorer performance in all cognitive domains except for attention. Amongst PD patients with MCI, those with cognitive anosognosia showed lower composite z-scores in the Stroop color reading test than those without. The Beck Depression Inventory score in the PD-NR group was lower than that in the PD-CU group and higher than that in the PD-CA group. The Cognitive Complaints Interview score mediated the association between cognitive anosognosia and Beck Depression Inventory score. CONCLUSIONS: Cognitive anosognosia in PD was associated with greater frontal dysfunction and lower depression. Since cognitive anosognosia has a harmful impact on PD patients and their caregivers due to overestimation of their abilities in everyday life, early identification of cognitive anosognosia in PD is important in management and prognosis.
Assuntos
Agnosia , Disfunção Cognitiva , Doença de Parkinson , Agnosia/etiologia , Cognição , Disfunção Cognitiva/etiologia , Estudos Transversais , Depressão/etiologia , Humanos , Testes Neuropsicológicos , Doença de Parkinson/complicaçõesRESUMO
BACKGROUND AND PURPOSE: The aim was to investigate the relationship between the serum urate (UA) levels and patterns of striatal dopamine depletion in patients with de novo Parkinson's disease (PD). METHODS: In all, 167 de novo PD patients who underwent 18 F-fluorinated N-3-fluoropropyl-2-beta-carboxymethoxy-3-beta-(4-iodophenyl) nortropane positron emission tomography scans were enrolled. After quantifying dopamine transporter (DAT) availability in each striatal subregion, sex-dependent patterns of striatal dopamine depletion were analysed by measuring (i) dopamine depletion in the other striatal subregions and posterior putamen (intersubregional ratio, ISR) and (ii) the interhemispheric asymmetry of dopamine depletion in the posterior putamen (asymmetric ratio, AR). RESULTS: The interaction analysis revealed a significant interaction effect of sex and serum UA levels on the ISR but not on the AR. The ISR was negatively correlated with the serum UA levels in all patients with PD (r = -0.156, P = 0.045), and this association was more prominent in male PD patients (r = -0.422, P < 0.001). However, no significant association between the AR and serum UA levels was found in any of the patients. In addition, serum UA levels were significantly associated with DAT availability in the posterior putamen on both the more affected side (r = 0.312, P = 0.005) and the less affected side (r = 0.312, P = 0.005) only in male PD patients. CONCLUSIONS: The present study demonstrated the potentially close sex-specific relationship between the serum UA levels and the anterior-posterior gradient of DAT patterns, suggesting a sex-specific protective effect of UA on nigrostriatal dopaminergic neurons in de novo PD.
Assuntos
Corpo Estriado/metabolismo , Dopamina/sangue , Dopamina/deficiência , Doença de Parkinson/metabolismo , Caracteres Sexuais , Ácido Úrico/sangue , Idoso , Corpo Estriado/diagnóstico por imagem , Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo , Feminino , Humanos , Masculino , Doença de Parkinson/diagnóstico por imagem , Tomografia por Emissão de PósitronsRESUMO
BACKGROUND AND PURPOSE: As a major antioxidant, uric acid (UA) is known to be associated with the clinical progression of Parkinson's disease (PD). This study investigated whether baseline UA levels are associated with the risk for levodopa-induced dyskinesia (LID) in PD in a sex-dependent manner. METHODS: In all, 152 patients with de novo PD (78 males and 74 females) who were followed up for >2 years were enrolled. The effect of baseline serum UA levels on LID-free survival was assessed by Cox regression, separately for sex, whilst being adjusted for potential confounding factors. The optimal UA level cut-off value to determine the high-risk group for LID was set using Contal and O'Quigley's method. RESULTS: Levodopa-induced dyskinesia developed in 23 (29.5%) male patients and 30 (40.5%) female patients. Cox regression showed a significant interaction between UA level and sex. Higher UA levels were associated with a higher risk for LID in male PD patients (hazard ratio 1.380; 95% confidence interval 1.038-1.835; P = 0.027), although this relationship was not observed in female PD patients. The optimal UA level cut-off for LID in male PD was 7.2 mg/dl, and the high UA group had a 5.7-fold higher risk of developing LID than the low UA group. CONCLUSIONS: Contrary to a presumptive beneficial role of UA, the present study demonstrated that higher UA levels are associated with increased risk of LID occurrence in male patients with PD, suggesting a sex-dependent role of UA in LID.
Assuntos
Discinesia Induzida por Medicamentos , Doença de Parkinson , Antiparkinsonianos/efeitos adversos , Discinesia Induzida por Medicamentos/etiologia , Feminino , Humanos , Levodopa/efeitos adversos , Masculino , Doença de Parkinson/tratamento farmacológico , Ácido ÚricoRESUMO
BACKGROUND AND PURPOSE: Subcortical structures are affected by neurodegeneration in Alzheimer's disease (AD) and Lewy body disease (LBD). Although the co-occurrence of AD and LBD pathologies and their possible interaction have been reported, the effect of AD and LBD on subcortical structures remains unknown. The effects of AD and LBD on subcortical atrophy and their relationship with cognitive dysfunction were investigated. METHODS: The cross-sectional study recruited 42 patients with pure AD related cognitive impairment (ADCI), 30 patients with pure LBD related cognitive impairment (LBCI), 58 patients with mixed ADCI and LBCI, and 29 normal subjects. A general linear model was used to compare subcortical volume and shape amongst the groups, to investigate the independent and interaction effects of ADCI and LBCI on subcortical shape and volume, and to analyze the relationship between subcortical volume and cognitive dysfunction in each group. RESULTS: Alzheimer's disease related cognitive impairment and LBCI were independently associated with subcortical atrophies in the hippocampus and amygdala and in the hippocampus and putamen respectively, but their interaction effect was not significant. Compared to the control group, the pure LBCI group exhibited additional local atrophies in the amygdala, caudate and thalamus. Subcortical atrophies correlated differently with cognitive dysfunction according to the underlying causes of cognitive dysfunction. CONCLUSIONS: The patterns of subcortical atrophies and their correlation with cognitive dysfunction differ according to the underlying AD, LBD or concomitant AD and LBD.
Assuntos
Doença de Alzheimer , Disfunção Cognitiva , Doença por Corpos de Lewy , Doença de Alzheimer/complicações , Atrofia , Disfunção Cognitiva/etiologia , Estudos Transversais , Humanos , Doença por Corpos de Lewy/complicaçõesRESUMO
AIMS: Many physiological and microbial characteristics influence the biocontrol performance of the biological control agents (BCAs) in agricultural fields. To implement effective biocontrol, the contribution of specific genes, mechanisms and traits to the biocontrol performance of BCAs need to be characterized and explored in greater detail. METHODS AND RESULTS: In this study, a transposon (Tn) mutant library using the BCA Pseudomonas fluorescens NBC275 (Pf275) was generated to explore genes and bacterial characteristics involved in antifungal activity and biocontrol performance. Among the Tn mutants, 205 strains showing variations in antifungal activity compared to wild-type (WT) were selected and further analysed for biocontrol efficacy against gray mold in pepper fruits. The genes involved in pyoverdine biosynthesis (pvdI and pvdD) and chitin-binding protein (gbpA) played essential roles in the antifungal activity and biocontrol capacity of Pf275. In addition, a mutation in phlD completely abolished the antifungal activity and significantly suppressed the biocontrol ability of the strain. Genes affecting antifungal activity of Pf275 significantly influenced swimming motility, which was identified as an important trait for the biocontrol ability of the bacterial strain. CONCLUSIONS: Overall, our results suggest that antifungal compound production, siderophore biosynthesis and swimming motility synergistically contribute to Pf275 biocontrol performance. The utility of this library was demonstrated by identifying genes for antagonism and biocontrol ability in this BCA strain. The functional roles of many genes identified as contributing to antagonism and in vivo biocontrol activity require further study. SIGNIFICANCE AND IMPACT OF THIS STUDY: Genes contributing to antifungal activity and biocontrol performance of P. fluorescens were identified and highlighted by Tn mutagenesis, which will give insight to improve the biocontrol performance of this BCA.
Assuntos
Antibiose/genética , Agentes de Controle Biológico , Genes Bacterianos , Pseudomonas fluorescens/genética , Antifúngicos/metabolismo , Agentes de Controle Biológico/metabolismo , Fungos/metabolismo , Locomoção/genética , Mutação , Doenças das Plantas/microbiologia , Sideróforos/genética , Sideróforos/metabolismoRESUMO
OBJECTIVE: We compared the efficacy and safety of tofacitinib and filgotinib in patients with rheumatoid arthritis (RA) showing inadequate response to conventional synthetic (cs) or biologic (b) disease-modifying anti-rheumatic drugs (DMARDs). METHODS: We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of tofacitinib and filgotinib in combination with methotrexate (MTX) in patients with RA exhibiting inadequate cs- or bDMARD response. RESULTS: Nine RCTs consisting of 5466 patients met the inclusion criteria. We obtained 15 pairwise comparisons, including 11 direct comparisons from 6 interventions. Tofacitinib 10â¯mgâ¯+ MTX and filgotinib 200â¯mgâ¯+ MTX were among the most effective treatments for active RA showing an inadequate cs- or bDMARD response, followed by tofacitinib 5â¯mgâ¯+ MTX, filgotinib 100â¯mgâ¯+ MTX, and adalimumabâ¯+ MTX. Ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that tofacitinib 10â¯mgâ¯+ MTX and filgotinib 200â¯mgâ¯+ MTX showed the highest probability of being the best treatment options in terms of ACR20 response rate (SUCRAâ¯= 0.898, 0.782), followed by tofacitinib 5â¯mgâ¯+ MTX (SUCRAâ¯= 0.602), filgotinib 100â¯mgâ¯+ MTX (SUCRAâ¯= 0.359), adalimumabâ¯+ MTX (SUCRAâ¯= 0.358), and placeboâ¯+ MTX (SUCRAâ¯= 0.001). No significant differences were observed in the incidence of serious adverse events after treatment with tofacitinibâ¯+ MTX, filgotinibâ¯+ MTX, adalimumabâ¯+ MTX, or placeboâ¯+ MTX. CONCLUSION: In patients with RA exhibiting an inadequate response to cs- or bDMARDs, tofacitinib 10â¯mgâ¯+ MTX and filgotinib 200â¯mgâ¯+ MTX were the most efficacious interventions and risks of serious adverse events did not differ between tofacitinib and filgotinib groups.
Assuntos
Antirreumáticos , Artrite Reumatoide , Piperidinas/uso terapêutico , Piridinas/uso terapêutico , Pirimidinas/uso terapêutico , Pirróis/uso terapêutico , Triazóis/uso terapêutico , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Teorema de Bayes , Quimioterapia Combinada , Humanos , Metotrexato/uso terapêutico , Metanálise em Rede , Piperidinas/efeitos adversos , Piridinas/efeitos adversos , Pirimidinas/efeitos adversos , Pirróis/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Triazóis/efeitos adversosRESUMO
OBJECTIVES: We assessed the relative efficacy and safety of once-daily administration of 15 and 30â¯mg upadacitinib (a JAK1-selective inhibitor) in patients with active rheumatoid arthritis (RA). METHODS: We conducted a Bayesian network meta-analysis to combine the direct and indirect evidence from randomized controlled trials (RCTs) that examined the efficacy and safety of upadacitinib in patients with active RA. RESULTS: Five RCTs involving 4381 patients met the inclusion criteria. There were 15 pairwise comparisons, including eight direct comparisons and six interventions. The ACR20 response rate was significantly higher in the upadacitinib 15 and 30â¯mgâ¯+ MTX (methotrexate) groups than in the MTX group (OR: 4.98, 95% CrI: 2.66-10.10; OR: 4.73, 95% CrI: 2.25-10.98). Adalimumab 40â¯mgâ¯+ MTX, upadacitinib 30â¯mg, and upadacitinib 15â¯mg groups showed a significantly higher ACR20 response rate than did the MTX group. Ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that upadacitinib 15â¯mgâ¯+ MTX was likely to achieve the best ACR20 response rate (SUCRAâ¯= 0.838), followed by upadacitinib 30â¯mgâ¯+ MTX, adalimumab 40â¯mgâ¯+ MTX, upadacitinib 30â¯mg, upadacitinib 15â¯mg, and MTX (SUCRAâ¯= 0.784, 0.495, 0.471, 0.404, and 0.008, respectively). The safety based on the number of serious adverse events (SAEs) did not differ significantly among the six interventions. CONCLUSIONS: Upadacitinib 15 and 30â¯mg administration once daily in combination with MTX was the most efficacious intervention for active RA, with no significant risk for SAEs.
Assuntos
Antirreumáticos , Artrite Reumatoide , Antirreumáticos/administração & dosagem , Artrite Reumatoide/tratamento farmacológico , Teorema de Bayes , Quimioterapia Combinada , Compostos Heterocíclicos com 3 Anéis/administração & dosagem , Humanos , Metotrexato , Metanálise em Rede , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do TratamentoRESUMO
OBJECTIVE: This study systemically reviewed the evidence regarding the association between plasminogen activator inhibitor1 (PAI1) 4G/5G polymorphism and susceptibility to systemic lupus erythematous (SLE)/lupus nephritis (LN) and rheumatoid arthritis (RA) and the relationship between circulating PAI1 levels and SLE/LN and RA. METHODS: We conducted a meta-analysis on the association between the PAI1 4G/5G polymorphism and SLE/LN or RA risk and serum/plasma PAI1 levels in patients with SLE/LN and RA and healthy controls. RESULTS: Nine articles including 657 patients with SLE and 668 controls and 567 patients with RA and 772 controls were included. No association was revealed between SLE and PAI1 4G allele in all study subjects (odds ratio [OR]â¯= 0.944, 95% confidence interval [CI]â¯= 0.808-1.102, pâ¯= 0.463). Ethnicity-based stratification showed no association between the PAI1 4G allele and SLE among Europeans and Asians. No association was detected between LN and RA and the PAI1 4G allele (ORâ¯= 0.886, 95% CIâ¯= 0.713-1.102, pâ¯= 0.278; ORâ¯= 0.8736, 95% CIâ¯= 0.747-1.020, pâ¯= 0.088, respectively) or between SLE/LN and RA and the PAI1 4G/5G polymorphism using the recessive and dominant models and homozygote contrast. The circulating PAI1 level was significantly higher in the SLE group than in the control group (standardized mean difference [SMD]â¯= 0.337, 95% CIâ¯= 0.057-0.619, pâ¯= 0.019). However, serum/plasma PAI1 level showed no significant difference between RA and control group (SMDâ¯= 0.333, 95% CIâ¯= -0.6989-1.35, pâ¯= 0.527). CONCLUSIONS: There was no association between the PAI1 4G/5G polymorphism and SLE/LN and RA development and significantly higher levels of circulating PAI1 were observed in patients with SLE but not in those with RA.
Assuntos
Artrite Reumatoide/genética , Lúpus Eritematoso Sistêmico/genética , Inibidor 1 de Ativador de Plasminogênio/genética , Predisposição Genética para Doença , Humanos , Plasminogênio , Polimorfismo Genético/genéticaRESUMO
OBJECTIVE: This study systemically reviewed the evidence regarding associations between polymorphisms in interleukin-17 (IL-17) genes and osteoarthritis (OA) susceptibility, and the relationship between circulating IL-17 levels and OA. METHODS: We performed a meta-analysis of the associations between the IL-17A rs2275913 and IL-17F rs763780 polymorphisms and risk for OA and serum/plasma IL-17 levels in OA patients and controls. RESULTS: Eight studies including 2214 OA patients and 2474 controls were included. Our meta-analysis identified a significant association between OA and the AA genotype of the IL-17A rs2275913 polymorphism in a pooled cohort of affected individuals, compared to the case in a pooled cohort of control participants (ORâ¯= 1.516, 95% CIâ¯= 1.260-1.825, Pâ¯< 0.001), and a significant association between OA and the CC genotype of the IL-17F rs763780 polymorphism (ORâ¯= 2.257, 95% CIâ¯= 1.376-3.704, pâ¯= 0.001). OA site-based stratification identified an association between the AA genotype of the IL-17A rs2275913 polymorphism and the CC genotype of the IL-17F rs763780 polymorphism and knee OA, but not hip OA. Furthermore, the same patterns of significant associations between OA and the IL-17A rs2275913 and IL-17F rs763780 polymorphisms were identified based on homozygote contrasts. The OA patients showed significantly higher IL-17 levels than the control subjects (SMDâ¯= 1.830, 95% CIâ¯= 1.184-2.477, Pâ¯< 0.001). CONCLUSION: Our meta-analysis revealed associations between the IL-17A rs2275913 and IL-17F rs763780 polymorphisms and OA susceptibility, and the presence of significantly higher circulating IL-17 levels in OA patients.
Assuntos
Predisposição Genética para Doença , Interleucina-17 , Osteoartrite/genética , Povo Asiático , Estudos de Casos e Controles , Genótipo , Humanos , Interleucina-17/genética , Polimorfismo de Nucleotídeo ÚnicoRESUMO
OBJECTIVE: To investigate whether periodontitis is causally associated with risk of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). METHODS: We performed two-sample Mendelian randomization (MR) analysis using the inverse variance-weighted (IVW), weighted median, and MR-Egger regression methods on publicly available summary statistics datasets using a periodontitis genome-wide association study (GWAS) as an exposure and RA and SLE GWASs on individuals of European descent as outcomes. RESULTS: We selected 7 or 20 single-nucleotide polymorphisms from a periodontitis GWAS as instrumental variables for RA or SLE. The IVW method results support a causal association between periodontitis and RA (betaâ¯= 0.168, SEâ¯= 0.080, pâ¯= 0.035) and SLE (betaâ¯= 0.0001, SEâ¯= 0.0001, pâ¯= 0.046) risk; however, the weighted median approach did not indicate a significant causal association. MR-Egger regression revealed that directional pleiotropy was unlikely to be biasing the RA (interceptâ¯= -0.115, pâ¯= 0.078) or SLE results (interceptâ¯= 4.68E-05, pâ¯= 0.394); no significant causal association was found between periodontitis and RA and SLE. The MR estimates from the IVW, weighted median, and MR-Egger regression analyses were not consistent. CONCLUSION: Only the results of MR analysis by the IVW method indicated that periodontitis is likely causally associated with an increased risk of RA and SLE incidence. Our MR showed weak causal association between periodontitis and RA or SLE. These findings may assist in elucidating the underlying mechanisms of the effects of periodontitis on RA and SLE incidence.
Assuntos
Artrite Reumatoide , Lúpus Eritematoso Sistêmico , Periodontite , Artrite Reumatoide/epidemiologia , Artrite Reumatoide/genética , Estudo de Associação Genômica Ampla , Humanos , Lúpus Eritematoso Sistêmico/epidemiologia , Lúpus Eritematoso Sistêmico/genética , Análise da Randomização Mendeliana , Periodontite/epidemiologia , Periodontite/genética , Polimorfismo de Nucleotídeo Único/genéticaRESUMO
Obesity is a major disease that causes significant complications. Inhibition of preadipocyte proliferation has the potential to prevent obesity and metabolic diseases. Melatonin is a pineal gland hormone that has various effects on cells and tissues. In this research, we investigated whether melatonin induces apoptosis in 3T3-L1 preadipocytes. 3T3-L1 preadipocytes were cultured until confluence and then treated with 0, 10, 100, and 1000 µM melatonin for 1, 3, and 5 days. A cell viability assay kit was used for determining cell viability. Cell death marker proteins were assessed by Western blot analysis using GAPDH for control. Apoptotic morphological changes with nuclei fragmentation were observed using DAPI staining. Melatonin treatment decreased the phosphorylated extracellular signal-regulated kinases (p-ERK) activation while increasing the activation of caspase-3, 8, and 9. Furthermore, melatonin not only increased Bcl-2-associated X protein (Bax) but decreased B-cell lymphoma 2 (Bcl-2) expression as dose increases from 0 to 1000 µM. The melatonin treatment also suppressed the growth of preadipocytes with increasing concentration. These effects were attenuated by luzindole, a melatonin receptor antagonist and U0126, an inhibitor of p-ERK activation. In conclusion, melatonin can induce apoptosis of 3T3-L1 preadipocytes via p-ERK decrease.